Merck Biophama

Merck (operating as EMD Serono in the U.S. and Canada) is the healthcare business sector of Merck KGaA, a leading global science and technology company headquartered in Darmstadt, Germany. As the world's oldest pharmaceutical and chemical company, it focuses on delivering innovative therapies in oncology, neurology, immunology, and fertility, as well as maintaining a strong presence in cardiovascular, metabolic, and endocrinological diseases. Key products include the oncology treatment Erbitux, the multiple sclerosis therapies Mavenclad and Rebif, and the fertility treatment Gonal-f. Following the 2025 acquisition of SpringWorks Therapeutics, the company has significantly expanded its footprint in rare diseases. Merck Biopharma operates a robust R&D pipeline with a focus on antibody-drug conjugates and targeted small molecules. The company is committed to advancing specialty medicine to address significant unmet needs in chronic and life-threatening conditions.